Key result
In a pilot evaluation of 36 patients, NT-proBNP concentrations showed no significant differences between different antipsychotic groups over 21 days, though baseline variations were observed by age and cardiovascular history.
Why the study?
Does antipsychotic medication influence NT-proBNP concentration in patients initiating treatment?
Observational (n=36)
Assays were performed blind to clinical information
Yes
Does antipsychotic medication influence NT-proBNP concentration in patients initiating treatment?
Antipsychotic medication may influence plasma NT-proBNP concentrations, suggesting its potential utility as a biomarker for monitoring cardiovascular safety.
No takes yet. Share an insight, caveat, or question.
No significant NT-proBNP change seen in this pilot; leaves open its value as antipsychotic safety marker pending larger studies.
Kropp et al. (2005) conducted an observational in Schizophrenia, schizoaffective or affective disorder (n=36). Antipsychotic medication vs. Baseline (day 0) and between patient subgroups was evaluated on NT-proBNP concentration at days 0, 7, and 21. In a pilot evaluation of 36 patients, NT-proBNP concentrations showed no significant differences between different antipsychotic groups over 21 days, though baseline variations were observed by age and cardiovascular history.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: